copper depletion suppresses triple-negative breast cancer in mice. *Nat. Biotechnol.* **2021**, *39* (3), 357.

(698) Cherny, R. A.; Atwood, C. S.; Xilinas, M. E.; Gray, D. N.; Jones, W. D.; McLean, C. A.; Barnham, K. J.; Volitakis, I.; Fraser, F. W.; Kim, Y.; et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. *Neuron* **2001**, *30* (3), 665.

(699) Lawson, M. K.; Valko, M.; Cronin, M. T. D.; Jomová, K. Chelators in Iron and Copper Toxicity. *Curr. Pharm. Rep.* **2016**, *2*, 271.

(700) Small, W., Jr.; Molteni, A.; Kim, Y. T.; Taylor, J. M.; Ts'ao, C. H.; Ward, W. F. Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper. *Breast Cancer Res. Treat.* **1999**, *55* (3), 223.

(701) Xie, F.; Peng, F. Anti-Prostate Cancer Activity of 8-Hydroxyquinoline-2-Carboxaldehyde-Thiosemicarbazide Copper Complexes by Fluorescent Microscopic Imaging. *J. Fluoresc.* **2017**, *27* (6), 1937.

(702) Bisceglie, F.; Baldini, M.; Belicchi-Ferrari, M.; Buluggiu, E.; Careri, M.; Pelosi, G.; Pinelli, S.; Tarasconi, P. Metal complexes of retinoid derivatives with antiproliferative activity: synthesis, characterization and DNA interaction studies. *Eur. J. Med. Chem.* **2007**, *42* (5), 627.

(703) Fan, C.; Su, H.; Zhao, J.; Zhao, B.; Zhang, S.; Miao, J. A novel copper complex of salicylaldehyde pyrazole hydrazone induces apoptosis through up-regulating integrin beta4 in H322 lung carcinoma cells. *Eur. J. Med. Chem.* **2010**, *45* (4), 1438.

(704) Wang, F.; Jiao, P.; Qi, M.; Frezza, M.; Dou, Q. P.; Yan, B. Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry. *Curr. Med. Chem.* **2010**, *17* (25), 2685.

(705) Drew, S. C. Chelator PBT2 Forms a Ternary Cu(2+) Complex with beta-Amyloid That Has High Stability but Low Specificity. *Int. J. Mol. Sci.* **2023**, *24* (11), 9267.

(706) Summers, K. L.; Roseman, G.; Schilling, K. M.; Dolgova, N. V.; Pushie, M. J.; Sokaras, D.; Kroll, T.; Harris, H. H.; Millhauser, G. L.; Pickering, I. J.; et al. Alzheimer's Drug PBT2 Interacts with the Amyloid beta 1-42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs. *Inorg. Chem.* **2022**, *61* (37), 14626.

(707) Shrivastav, A.; Singh, N. K.; Tripathi, P.; George, T.; Dimmock, J. R.; Sharma, R. K. Copper(II) and manganese(III) complexes of N'-[(2-hydroxy phenyl) carbonothioyl] pyridine-2-carbohydrazide: novel therapeutic agents for cancer. *Biochimie* **2006**, *88* (9), 1209.

(708) Ainscough, E. W.; Brodie, A. M.; Denny, W. A.; Finlay, G. J.; Gothe, S. A.; Ranford, J. D. Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure-activity relationships. *J. Inorg. Biochem.* **1999**, *77* (3-4), 125.

(709) Prachayasittikul, V.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. *Drug Des. Devel. Ther.* **2013**, *7*, 1157.

(710) Chakraborty, A.; Kumar, P.; Ghosh, K.; Roy, P. Evaluation of a Schiff base copper complex compound as potent anticancer molecule with multiple targets of action. *Eur. J. Pharmacol.* **2010**, *647* (1-3), 1.

(711) Lian, W. J.; Wang, X. T.; Xie, C. Z.; Tian, H.; Song, X. Q.; Pan, H. T.; Qiao, X.; Xu, J. Y. Mixed-ligand copper(ii) Schiff base complexes: the role of the co-ligand in DNA binding, DNA cleavage, protein binding and cytotoxicity. *Dalton Trans.* **2016**, *45* (22), 9073.

(712) Tang, D.; Kroemer, G.; Kang, R. Targeting cuproplasia and cuproptosis in cancer. *Nat. Rev. Clin. Oncol.* **2024**, *21* (5), 370.

(713) Pan, Z.; Huang, L.; Gan, Y.; Xia, Y.; Yu, W. The Molecular Mechanisms of Cuproptosis and Small-Molecule Drug Design in Diabetes Mellitus. *Molecules* **2024**, *29* (12), 2852.

(714) Maret, W. The redox biology of redox-inert zinc ions. *Free Radic. Biol. Med.* **2019**, *134*, 311.

(715) Maret, W.; Vallee, B. L. Thiolate ligands in metallothionein confer redox activity on zinc clusters. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95* (7), 3478.

(716) Murakami, M.; Hirano, T. Intracellular zinc homeostasis and zinc signaling. *Cancer Sci.* **2008**, *99* (8), 1515.

(717) Bafaro, E.; Liu, Y.; Xu, Y.; Dempski, R. E. The emerging role of zinc transporters in cellular homeostasis and cancer. *Signal Transduct. Target Ther.* **2017**, *2*, 17029.

(718) Jeong, J.; Eide, D. J. The SLC39 family of zinc transporters. *Mol. Aspects Med.* **2013**, *34* (2-3), 612.

(719) Feske, S.; Wulff, H.; Skolnik, E. Y. Ion channels in innate and adaptive immunity. *Annu. Rev. Immunol.* **2015**, *33*, 291.

(720) Espinoza, A.; Le Blanc, S.; Olivares, M.; Pizarro, F.; Ruz, M.; Arredondo, M. Iron, copper, and zinc transport: inhibition of divalent metal transporter 1 (DMT1) and human copper transporter 1 (hCTR1) by shRNA. *Biol. Trace Elem. Res.* **2012**, *146* (2), 281.

(721) Sun, C.; He, B.; Gao, Y.; Wang, X.; Liu, X.; Sun, L. Structural insights into the calcium-coupled zinc export of human ZnT1. *Sci. Adv.* **2024**, *10* (17), eadk5128.

(722) Mocchegiani, E.; Giacconi, R.; Muti, E.; Cipriano, C.; Costarelli, L.; Tesei, S.; Gasparini, N.; Malavolta, M. Zinc-bound metallothioneins and immune plasticity: lessons from very old mice and humans. *Immun. Ageing* **2007**, *4*, 7.

(723) Baltaci, A. K.; Yuce, K.; Mogulkoc, R. Zinc Metabolism and Metallothioneins. *Biol. Trace Elem. Res.* **2018**, *183* (1), 22.

(724) Zhang, C.; Sui, D.; Zhang, T.; Hu, J. Molecular Basis of Zinc-Dependent Endocytosis of Human ZIP4 Transceptor. *Cell Rep.* **2020**, *31* (4), 107582.

(725) Beyersmann, D.; Haase, H. Functions of zinc in signaling, proliferation and differentiation of mammalian cells. *Biometals* **2001**, *14* (3-4), 331.

(726) Weiss, A.; Murdoch, C. C.; Edmonds, K. A.; Jordan, M. R.; Monteith, A. J.; Perera, Y. R.; Rodriguez Nassif, A. M.; Petoletti, A. M.; Beavers, W. N.; Munneke, M. J.; et al. Zn-regulated GTPase metalloprotein activator 1 modulates vertebrate zinc homeostasis. *Cell* **2022**, *185* (12), 2148.

(727) Maret, W. Zinc in Cellular Regulation: The Nature and Significance of "Zinc Signals". *Int. J. Mol. Sci.* **2017**, *18* (11), 2285.

(728) Maret, W. Crosstalk of the group IIa and IIb metals calcium and zinc in cellular signaling. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98* (22), 12325.

(729) MacDonald, R. S. The role of zinc in growth and cell proliferation. *J. Nutr.* **2000**, *130*, 1500S.

(730) Cassandri, M.; Smirnov, A.; Novelli, F.; Pitolli, C.; Agostini, M.; Malewicz, M.; Melino, G.; Raschella, G. Zinc-finger proteins in health and disease. *Cell Death Discovery* **2017**, *3*, 17071.

(731) Bendellaa, M.; Lelievre, P.; Coll, J. L.; Sancey, L.; Deniaud, A.; Busser, B. Roles of zinc in cancers: From altered metabolism to therapeutic applications. *Int. J. Cancer* **2024**, *154* (1), 7.

(732) Supasai, S.; Aimo, L.; Adamo, A. M.; Mackenzie, G. G.; Oteiza, P. I. Zinc deficiency affects the STAT1/3 signaling pathways in part through redox-mediated mechanisms. *Redox Biol.* **2017**, *11*, 469.

(733) Hogstrand, C.; Kille, P.; Ackland, M. L.; Hiscox, S.; Taylor, K. M. A mechanism for epithelial-mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3). *Biochem. J.* **2013**, *455* (2), 229.

(734) Yamasaki, S.; Sakata-Sogawa, K.; Hasegawa, A.; Suzuki, T.; Kabu, K.; Sato, E.; Kurosaki, T.; Yamashita, S.; Tokunaga, M.; Nishida, K.; et al. Zinc is a novel intracellular second messenger. *J. Cell Biol.* **2007**, *177* (4), 637.

(735) Wu, W.; Jaspers, I.; Zhang, W.; Graves, L. M.; Samet, J. M. Role of Ras in metal-induced EGF receptor signaling and NF-kappaB activation in human airway epithelial cells. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2002**, *282* (5), L1040.

(736) Chen, B.; Yu, P.; Chan, W. N.; Xie, F.; Zhang, Y.; Liang, L.; Leung, K. T.; Lo, K. W.; Yu, J.; Tse, G. M. K.; Kang, W.; To, K. F. Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets. *Signal Transduct. Target Ther.* **2024**, *9*, 6.

(737) Liu, M. J.; Bao, S.; Galvez-Peralta, M.; Pyle, C. J.; Rudawsky, A. C.; Pavlovicz, R. E.; Killilea, D. W.; Li, C.; Nebert, D. W.; Wewers, M. D.; et al. ZIP8 regulates host defense through zinc-mediated inhibition of NF-kappaB. *Cell Rep.* **2013**, *3* (2), 386.
(738) Slepchenko, K. G.; Holub, J. M.; Li, Y. V. Intracellular zinc increase affects phosphorylation state and subcellular localization of protein kinase C delta (delta). *Cell Signal* **2018**, *44*, 148.

(739) Sim, E. Z.; Enomoto, T.; Shiraki, N.; Furuta, N.; Kashio, S.; Kambe, T.; Tsuyama, T.; Arakawa, A.; Ozawa, H.; Yokoyama, M.; et al. Methionine metabolism regulates pluripotent stem cell pluripotency and differentiation through zinc mobilization. *Cell Rep.* **2022**, *40* (3), 111120.

(740) Duncan, F. E.; Que, E. L.; Zhang, N.; Feinberg, E. C.; O'Halloran, T. V.; Woodruff, T. K. The zinc spark is an inorganic signature of human egg activation. *Sci. Rep* **2016**, *6*, 24737.

(741) Seto, E.; Yoshida, M. Erasers of histone acetylation: the histone deacetylase enzymes. *Cold Spring Harb. Perspect. Biol.* **2014**, *6* (4), No. a018713.

(742) Gallinari, P.; Marco, S. D.; Jones, P.; Pallaoro, M.; Steinkuhler, C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. *Cell Res.* **2007**, *17*, 195.

(743) Jen, J.; Wang, Y. C. Zinc finger proteins in cancer progression. *J. Biomed. Sci.* **2016**, *23*, 53.

(744) Wang, J.; Zhao, H.; Xu, Z.; Cheng, X. Zinc dysregulation in cancers and its potential as a therapeutic target. *Cancer Biol. Med.* **2020**, *17*(3), 612.

(745) Zou, X.; Ma, L.; Zhang, Y.; Zhang, Q.; Xu, C.; Zhang, D.; Chu, Y.; Zhang, J.; Li, M.; Zhang, H.; Wang, J.; Peng, C.; Wei, G.; Wu, Y.; Hou, Z.; Jia, H. GATA zinc finger protein p66beta promotes breast cancer cell migration by acting as a co-activator of Snail. *Cell Death Dis.* **2023**, *14* (6), 382.

(746) Kim, J.; Park, A.; Hwang, J.; Zhao, X.; Kwak, J.; Kim, H. W.; Ku, M.; Yang, J.; Kim, T. I.; Jeong, K. S.; et al. KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1(+) stem cells. *Cell Rep.* **2022**, *40* (3), 111077.

(747) Hogstrand, C.; Kille, P.; Nicholson, R. I.; Taylor, K. M. Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. *Trends Mol. Med.* **2009**, *15* (3), 101.

(748) Taylor, K. M.; Hiscox, S.; Nicholson, R. I.; Hogstrand, C.; Kille, P. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. *Sci. Signal* **2012**, *5* (210), ra11.

(749) Nolin, E.; Gans, S.; Llamas, L.; Bandyopadhyay, S.; Brittain, S. M.; Bernasconi-Elias, P.; Carter, K. P.; Loureiro, J. J.; Thomas, J. R.; Schirle, M.; et al. Discovery of a ZIP7 inhibitor from a Notch pathway screen. *Nat. Chem. Biol.* **2019**, *15* (2), 179.

(750) Ziliotto, S.; Ogle, O.; Taylor, K. M. Targeting Zin(II) Signalling to Prevent Cancer. *Met. Ions. Life Sci.* **2018**, *18*, 23.

(751) Jin, J.; Guo, Y.; Dong, X.; Liu, J.; He, Y. Methylation-associated silencing of miR-193b improves the radiotherapy sensitivity of esophageal cancer cells by targeting cyclin D1 in areas with zinc deficiency. *Radiother. Oncol.* **2020**, *150*, 104.

(752) Nimmanon, T.; Ziliotto, S.; Ogle, O.; Burt, A.; Gee, J. M. W.; Andrews, G. K.; Kille, P.; Hogstrand, C.; Maret, W.; Taylor, K. M. The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis. *Cell. Mol. Life Sci.* **2021**, *78* (4), 1781.

(753) Barroso-Sousa, R.; Tolaney, S. M. Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond. *BioDrugs* **2021**, *35* (2), 159.

(754) Saravanan, R.; Balasubramanian, V.; Swaroop Balamurugan, S. S.; Ezhil, I.; Afañaan, Z.; John, J.; Sundaram, S.; Gouthaman, S.; Pakala, S. B.; Rayala, S. K.; et al. Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer. *J. Cell Physiol.* **2022**, *237* (11), 4132.

(755) Seok, J.; Kwak, H. J.; Kwak, Y.; Lee, M.; Park, K. S.; Kim, A.; Cho, S. G. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer. *J. Transl. Med.* **2023**, *21*, 129.

(756) Aguiirre-Portoles, C.; Payne, R.; Trautz, A.; Foskett, J. K.; Natale, C. A.; Seykora, J. T.; Ridky, T. W. ZIP9 Is a Druggable Determinant of Sex Differences in Melanoma. *Cancer Res.* **2021**, *81* (23), S991.

(757) Li, H.; Shen, X.; Ma, M.; Liu, W.; Yang, W.; Wang, P.; Cai, Z.; Mi, R.; Lu, Y.; Zhuang, J.; Jiang, Y.; Song, Y.; Wu, Y.; Shen, H. ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway. *J. Exp. Clin. Cancer Res.* **2021**, *40*, 340.

(758) Hashemi, M.; Ghavami, S.; Eshraghi, M.; Booy, E. P.; Los, M. Cytotoxic effects of intra and extracellular zinc chelation on human breast cancer cells. *Eur. J. Pharmacol.* **2007**, *557* (1), 9.

(759) Donadelli, M.; Dalla Pozza, E.; Costanzo, C.; Scupoli, M. T.; Scarpa, A.; Palmieri, M. Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/ proliferative genes. *J. Cell Biochem.* **2008**, *104* (1), 202.

(760) Donadelli, M.; Dalla Pozza, E.; Scupoli, M. T.; Costanzo, C.; Scarpa, A.; Palmieri, M. Intracellular zinc increase inhibits p53(-/-) pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis. *Biochim. Biophys. Acta* **2009**, *1793* (2), 273.

(761) Yu, Z.; Yu, Z.; Chen, Z.; Yang, L.; Ma, M.; Lu, S.; Wang, C.; Teng, C.; Nie, Y. Zinc chelator TPEN induces pancreatic cancer cell death through causing oxidative stress and inhibiting cell autophagy. *J. Cell Physiol.* **2019**, *234* (11), 20648.

(762) Regland, B.; Lehmann, W.; Abedini, I.; Blennow, K.; Jonsson, M.; Karlsson, I.; Sjogren, M.; Wallin, A.; Xilinas, M.; Gottfries, C. G. Treatment of Alzheimer's disease with cloquinol. *Dement. Geriatr. Cogn. Disord.* **2001**, *12* (6), 408.

(763) Ritchie, C. W.; Bush, A. I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q. X.; Tammer, A.; et al. Metal-protein attenuation with iodochlorhydroxyquin (cioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. *Arch. Neurol.* **2003**, *60* (12), 1685.

(764) Costello, L. C.; Franklin, R. B. Cytotoxic/tumor suppressor role of zinc for the treatment of cancer: an enigma and an opportunity. *Expert Rev. Anticancer Ther.* **2012**, *12* (1), 121.

(765) Schmitt, S. M.; Frezza, M.; Dou, Q. P. New applications of old metal-binding drugs in the treatment of human cancer. *Front. Biosci.* **2012**, *4*, 375.

(766) Brar, S. S.; Grigg, C.; Wilson, K. S.; Holder, W. D., Jr; Dreau, D.; Austin, C.; Foster, M.; Ghio, A. J.; Whorton, A. R.; Stowell, G. W.; et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. *Mol. Cancer Ther.* **2004**, *3* (9), 1049.

(767) Ho, E. Zinc deficiency, DNA damage and cancer risk. *J. Nutr. Biochem.* **2004**, *15* (10), 572.

(768) Ahel, I.; Ahel, D.; Matsusaka, T.; Clark, A. J.; Pines, J.; Boulton, S. J.; West, S. C. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. *Nature* **2008**, *451* (7174), 81.

(769) Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. *Nat. Rev. Drug Discovery* **2006**, *5* (9), 769.

(770) Libby, E. N.; Becker, P. S.; Burwick, N.; Green, D. J.; Holmberg, L.; Bensinger, W. I. Panobinostat: a review of trial results and future prospects in multiple myeloma. *Expert Rev. Hematol.* **2015**, *8* (1), 9.

(771) West, A. C.; Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. *J. Clin. Invest.* **2014**, *124* (1), 30.

(772) Li, Y.; Seto, E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. *Cold Spring Harb. Perspect Med.* **2016**, *6*, a026831.

(773) Hu, Z.; Wei, F.; Su, Y.; Wang, Y.; Shen, Y.; Fang, Y.; Ding, J.; Chen, Y. Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression. *Signal. Transduct. Target Ther.* **2023**, *8*, 11.

(774) Clements, M. E.; Holtslander, L.; Johnson, J. R.; Johnson, R. W. Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy. *JBMR Plus* **2023**, *7* (3), e10694.

(775) Chatterjee, A.; Rodger, E. J.; Eccles, M. R. Epigenetic drivers of tumorigenesis and cancer metastasis. *Semin. Cancer Biol.* **2018**, *51*, 149.
(776) Wessels, I.; Maywald, M.; Rink, L. Zinc as a Gatekeeper of Immune Function. *Nutrients* **2017**, *9* (12), 1286.

(777) Maywald, M.; Wessels, I.; Rink, L. Zinc Signals and Immunity. *Int. J. Mol. Sci.* **2017**, *18* (10), 2222.

(778) Dardenne, M. Zinc and immune function. *Eur. J. Clin. Nutr.* **2002**, *56*, S20.

(779) Gammoh, N. Z.; Rink, L. Zinc in Infection and Inflammation. *Nutrients* **2017**, *9*, 624.

(780) Kim, B.; Lee, W. W. Regulatory Role of Zinc in Immune Cell Signaling. *Mol. Cells* **2021**, *44* (5), 335.

(781) Jarosz, M.; Olbert, M.; Wyszogrodzka, G.; Młyniec, K.; Librowski, T. Antioxidant and anti-inflammatory effects of zinc. Zinc-dependent NF-kappaB signaling. *Inflammopharmacology* **2017**, *25* (1), 11.

(782) Rolles, B.; Maywald, M.; Rink, L. Intracellular zinc during cell activation and zinc deficiency. *J. Trace Elem. Med. Biol.* **2021**, *68*, 126864.

(783) Rice, J. M.; Zweifach, A.; Lynes, M. A. Metallothionein regulates intracellular zinc signaling during CD4(+) T cell activation. *BMC Immunol.* **2016**, *17*, 13.

(784) Haase, H.; Rink, L. The immune system and the impact of zinc during aging. *Immun. Ageing* **2009**, *6*, 9.

(785) Haase, H.; Rink, L. Functional significance of zinc-related signaling pathways in immune cells. *Annu. Rev. Nutr.* **2009**, *29*, 133.

(786) Yu, M.; Lee, W. W.; Tomar, D.; Pryshchep, S.; Czesnikiewicz-Guzik, M.; Lamar, D. L.; Li, G.; Singh, K.; Tian, L.; Weyand, C. M.; et al. Regulation of T cell receptor signaling by activation-induced zinc influx. *J. Exp. Med.* **2011**, *208* (4), 775.

(787) Read, S. A.; O'Connor, K. S.; Suppiah, V.; Ahlenstiel, C. L. E.; Obeid, S.; Cook, K. M.; Cunningham, A.; Douglas, M. W.; Hogg, P. J.; Booth, D.; George, J.; Ahlenstiel, G. Zinc is a potent and specific inhibitor of IFN-lambda3 signalling. *Nat. Commun.* **2017**, *8*, 15245.

(788) Browning, J. D.; MacDonald, R. S.; Thornton, W. H.; O'Dell, B. L. Reduced food intake in zinc deficient rats is normalized by megestrol acetate but not by insulin-like growth factor-I. *J. Nutr.* **1998**, *128* (1), 136.

(789) Kagara, N.; Tanaka, N.; Noguchi, S.; Hirano, T. Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells. *Cancer Sci.* **2007**, *98* (5), 692.

(790) Ben Abdallah, S.; Mhalla, Y.; Trabelsi, I.; Sekma, A.; Youssef, R.; Bel Haj Ali, K.; Ben Soltane, H.; Yacoubi, H.; Msolli, M. A.; Stambouli, N.; et al. Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial. *Clin. Infect. Dis.* **2023**, *76* (2), 185.

(791) Rodriguez, J. A. M.; Bifano, M.; Roca Goma, E.; Plasencia, C. M.; Torralba, A. O.; Font, M. S.; Millan, P. R. Effect and Tolerability of a Nutritional Supplement Based on a Synergistic Combination of beta-Glucans and Selenium- and Zinc-Enriched Saccharomyces cerevisiae (ABB C1((R))) in Volunteers Receiving the Influenza or the COVID-19 Vaccine: A Randomized, Double-Blind, Placebo-Controlled Study. *Nutrients* **2021**, *13* (12), 4347.

(792) Jayaraman, A. K.; Jayaraman, S. Increased level of exogenous zinc induces cytotoxicity and up-regulates the expression of the ZnT-1 zinc transporter gene in pancreatic cancer cells. *J. Nutr. Biochem.* **2011**, *22* (1), 79.

(793) Uzzo, R. G.; Crispen, P. L.; Golovine, K.; Makhov, P.; Horwitz, E. M.; Kolenko, V. M. Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression. *Carcinogenesis* **2006**, *27* (10), 1980.

(794) Lin, L. C.; Que, J.; Lin, L. K.; Lin, F. C. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. *Int. J. Radiat. Oncol. Biol. Phys.* **2006**, *65* (3), 745.

(795) Suh, S. W.; Chen, J. W.; Motamedi, M.; Bell, B.; Listiak, K.; Pons, N. F.; Danscher, G.; Frederickson, C. J. Evidence that synaptically-released zinc contributes to neuronal injury after traumatic brain injury. *Brain Res.* **2000**, *852* (2), 268.

(796) Canzoniero, L. M.; Manzerra, P.; Sheline, C. T.; Choi, D. W. Membrane-permeant chelators can attenuate Zn2+-induced cortical neuronal death. *Neuropharmacology* **2003**, *45* (3), 420.

(797) Dobsak, P.; Courderot-Masuyer, C.; Zeller, M.; Vergely, C.; Laubriet, A.; Assem, M.; Eicher, J. C.; Teyssier, J. R.; Wolf, J. E.; Rochette, L. Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia. *J. Cardiovasc. Pharmacol.* **1999**, *34* (5), 651.

(798) Albers, G. W. Advances in intravenous thrombolytic therapy for treatment of acute stroke. *Neurology* **2001**, *57*, S77.

(799) Lim, W. F.; Mohamad Yusof, M. I.; Teh, L. K.; Salleh, M. Z. Significant Decreased Expressions of CaN, VEGF, SLC39A6 and SFRP1 in MDA-MB-231 Xenograft Breast Tumor Mice Treated with Moringa oleifera Leaves and Seed Residue (MOLSR) Extracts. *Nutrients* **2020**, *12*, 2993.

(800) Changizzadeh, P. N.; Mukkamalla, S. K. R.; Armenio, V. A. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma. *J. Immunother. Cancer* **2017**, *5*, 97.

(801) Li, M.; Zhang, Y.; Bharadwaj, U.; Zhai, Q. J.; Ahern, C. H.; Fisher, W. E.; Brunicardi, F. C.; Logsdon, C. D.; Chen, C.; Yao, Q. Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts. *Clin. Cancer Res.* **2009**, *15* (19), 5993.

(802) Shi, X.; Yang, J.; Liu, M.; Zhang, Y.; Zhou, Z.; Luo, W.; Fung, K. M.; Xu, C.; Bronze, M. S.; Houchen, C. W.; et al. Circular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2-AKT-TGF-beta Signaling Axis in Pancreatic Cancer. *Gastroenterology* **2022**, *162* (7), 2004.

(803) Wu, D. M.; Liu, T.; Deng, S. H.; Han, R.; Xu, Y. SLC39A4 expression is associated with enhanced cell migration, cisplatin resistance, and poor survival in non-small cell lung cancer. *Sci. Rep.* **2017**, *7*, 7211.

(804) Golub, A. G.; Bdzhola, V. G.; Briukhovetska, N. V.; Balanda, A. O.; Kukharenko, O. P.; Kotey, I. M.; Ostrynska, O. V.; Yarmoluk, S. M. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. *Eur. J. Med. Chem.* **2011**, *46* (3), 870.

(805) Pandurangan, M.; Enkhtaivan, G.; Kim, D. H. Anticancer studies of synthesized ZnO nanoparticles against human cervical carcinoma cells. *J. Photochem. Photobiol., B* **2016**, *158*, 206.

(806) Wahab, R.; Kaushik, N.; Khan, F.; Kaushik, N. K.; Choi, E. H.; Musarrat, J.; Al-Khedairy, A. A. Self-Styled ZnO Nanostructures Promotes the Cancer Cell Damage and Supresses the Epithelial Phenotype of Glioblastoma. *Sci. Rep.* **2016**, *6*, 19950.

(807) Wiesmann, N.; Kluenker, M.; Demuth, P.; Brenner, W.; Tremel, W.; Brieger, J. Zinc overload mediated by zinc oxide nanoparticles as innovative anti-tumor agent. *J. Trace Elem. Med. Biol.* **2019**, *51*, 226.

(808) Yang, R.; Wu, R.; Mei, J.; Hu, F. R.; Lei, C. J. Zinc oxide nanoparticles promotes liver cancer cell apoptosis through inducing autophagy and promoting p53. *Eur. Rev. Med. Pharmacol. Sci.* **2021**, *25* (3), 1557.

(809) Padmanabhan, A.; Kaushik, M.; Niranjan, R.; Richards, J. S.; Ebright, B.; Venkatasubbu, G. D. Zinc Oxide nanoparticles induce oxidative and proteotoxic stress in ovarian cancer cells and trigger apoptosis Independent of p53-mutation status. *Appl. Surf. Sci.* **2019**, *487*, 807.

(810) Islam, M. R.; Attia, J.; Ali, L.; McEvoy, M.; Selim, S.; Sibbritt, D.; Akhter, A.; Akter, S.; Peel, R.; Faruque, O.; et al. Zinc supplementation for improving glucose handling in pre-diabetes: A double blind randomized placebo controlled pilot study. *Diabetes Res. Clin. Pract.* **2016**, *115*, 39.

(811) Foster, M.; Petocz, P.; Samman, S. Inflammation markers predict zinc transporter gene expression in women with type 2 diabetes mellitus. *J. Nutr. Biochem.* **2013**, *24* (9), 1655.

(812) Fung, E. B.; Ahmad, T.; Killilea, D. W.; Hussain, R.; Lal, A. Zinc supplementation improves markers of glucose homeostasis in thalassaemia. *Br. J. Hamaetol.* **2020**, *190* (3), e162.

(813) Bobat, R.; Coovadia, H.; Stephen, C.; Naidoo, K. L.; McKerrow, N.; Black, R. E.; Moss, W. J. Safety and efficacy of zinc supplementation
for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. *Lancet* 2005, 366 (9500), 1862.

(814) Fung, E. B.; Kwiatkowski, J. L.; Huang, J. N.; Gildengorin, G.; King, J. C.; Vichinsky, E. P. Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial. *Am. J. Clin. Nutr.* 2013, 98 (4), 960.

(815) Ribeiro, S. M.; Braga, C. B.; Peria, F. M.; Domenici, F. A.; Martinez, E. Z.; Feres, O.; Ribeiro da Rocha, J. J.; de Carvalho da Cunha, S. F. Effect of Zinc Supplementation on Antioxidant Defenses and Oxidative Stress Markers in Patients Undergoing Chemotherapy for Colorectal Cancer: a Placebo-Controlled, Prospective Randomized Trial. *Biol. Trace Elem. Res.* 2016, 169, 8.

(816) Roy, S. K.; Hossain, M. J.; Khatun, W.; Chakraborty, B.; Chowdhury, S.; Begum, A.; Mah-e-Muneer, S.; Shafique, S.; Khanam, M.; Chowdhury, R. Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial. *BMJ. 2008*, 336 (7638), 266.

(817) Nazem, M. R.; Asadi, M.; Adelipour, M.; Jabbari, N.; Allameh, A. Zinc supplementation ameliorates type 2 diabetes markers through the enhancement of total antioxidant capacity in overweight patients. *Postgrad. Med. J.* 2023, 99 (1174), 862.

(818) Bao, B.; Prasad, A. S.; Beck, F. W.; Fitzgerald, J. T.; Snell, D.; Bao, G. W.; Singh, T.; Cardozo, L. J. Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. *Am. J. Clin. Nutr.* 2010, 91 (6), 1634.

(819) Faghfouri, A. H.; Baradaran, B.; Khabbazi, A.; Abdoli Shadbad, M.; Papi, S.; Faghfuri, E.; Khajebishak, Y.; Rahmani, S.; Tolou Hayat, P.; Alipour, B. Regulation of NLRP3 inflammasome by zinc supplementation in Behcet's disease patients: A double-blind, randomized placebo-controlled clinical trial. *Int. Immunopharmacol.* 2022, 109, 108825.

(820) Faghfouri, A. H.; Khabbazi, A.; Baradaran, B.; Khajebishak, Y.; Baghbani, E.; Noorolyai, S.; Rahmani, S.; Seyyed Shoura, S. M.; Alipour, M.; Alipour, B. Immunomodulatory and clinical responses to zinc gluconate supplementation in patients with Behcet's disease: A double-blind, randomized placebo-controlled clinical trial. *Clin. Nutr.* 2022, 41 (5), 1083.

(821) Veenemans, J.; Milligan, P.; Prentice, A. M.; Schouten, L. R.; Inja, N.; van der Heijden, A. C.; de Boer, L. C.; Jansen, E. J.; Koopmans, A. E.; Enthoven, W. T.; et al. Effect of supplementation with zinc and other micronutrients on malaria in Tanzanian children: a randomised trial. *PLoS Med.* 2011, 8 (11), e1001125.

(822) Guo, C. H.; Chen, P. C.; Hsu, G. S.; Wang, C. L. Zinc supplementation alters plasma aluminum and selenium status of patients undergoing dialysis: a pilot study. *Nutrients* 2013, 5 (4), 1456.

(823) Qiao, Y. L.; Dawsey, S. M.; Kamangar, F.; Fan, J. H.; Abnet, C. C.; Sun, X. D.; Johnson, L. L.; Gail, M. H.; Dong, Z. W.; Yu, B.; et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. *J. Natl. Cancer Inst.* 2009, 101 (7), 507.

(824) Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. *Science* 1994, 265 (5175), 1093.

(825) Dardenne, M.; Pleau, J. M.; Nabarra, B.; Lefrancier, P.; Derrien, M.; Choay, J.; Bach, J. F. Contribution of zinc and other metals to the biological activity of the serum thymic factor. *Proc. Natl. Acad. Sci. U.S.A.* 1982, 79 (17), 5370.

(826) Codd, R.; Braich, N.; Liu, J.; Soe, C. Z.; Pakchung, A. A. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. *Int. J. Biochem. Cell Biol.* 2009, 41 (4), 736.

(827) Tumolo, M.; Ancona, V.; De Paola, D.; Losacco, D.; Campanale, C.; Massarelli, C.; Uricchio, V. F. Chromium Pollution in European Water, Sources, Health Risk, and Remediation Strategies: An Overview. *Int. J. Environ. Res. Public Health* 2020, 17 (15), 5438.

(828) Rehder, D. The role of vanadium in biology. *Metallomics* 2015, 7 (5), 730.

(829) Aisen, P.; Aasa, R.; Redfield, A. G. The chromium, manganese, and cobalt complexes of transferrin. *J. Biol. Chem.* 1969, 244 (17), 4628.

(830) Okamoto, S.; Eltis, L. D. The biological occurrence and trafficking of cobalt. *Metallomics* 2011, 3 (10), 963.

(831) Pruss, R. M.; Akeson, R. L.; Racke, M. M.; Wilburn, J. L. Agonist-activated cobalt uptake identifies divalent cation-permeable kainate receptors on neurons and glial cells. *Neuron* 1991, 7 (3), 509.

(832) Seetharam, B.; Li, N. Transcobalamin II and its cell surface receptor. *Vitam. Horm.* 2000, 59, 337.

(833) McCorvie, T. J.; Ferreira, D.; Yue, W. W.; Froese, D. S. The complex machinery of human cobalamin metabolism. *J. Inherit. Metab. Dis.* 2023, 46 (3), 406.

(834) Morrissey, J.; Baxter, I. R.; Lee, J.; Li, L.; Lahner, B.; Grotz, N.; Kaplan, J.; Salt, D. E.; Guerinot, M. L. The ferroportin metal efflux proteins function in iron and cobalt homeostasis in Arabidopsis. *Plant Cell* 2009, 21 (10), 3326.

(835) Onodera, R.; Asakawa, S.; Segawa, R.; Mizuno, N.; Ogasawara, K.; Hiratsuka, M.; Hirasawa, N. Zinc ions have a potential to attenuate both Ni ion uptake and Ni ion-induced inflammation. *Sci. Rep.* 2018, 8, 2911.

(836) Sunderman, F. W., Jr. A review of the metabolism and toxicology of nickel. *Ann. Clin. Lab. Sci.* 1977, 7 (5), 377.

(837) Sunderman, F. W., Jr.; Decsy, M. I.; McNeely, M. D. Nickel metabolism in health and disease. *Ann. N.Y. Acad. Sci.* 1972, 199, 300.

(838) Zambelli, B.; Ciurli, S. Nickel and human health. *Met. Ions Life Sci.* 2013, 13, 321.

(839) Munoz, A.; Costa, M. Elucidating the mechanisms of nickel compound uptake: a review of particulate and nano-nickel endocytosis and toxicity. *Toxicol. Appl. Pharmacol.* 2012, 260 (1), 1.

(840) Hagen, W. Cellular uptake of molybdenum and tungsten. *Coord. Chem. Rev.* 2011, 255, 1117.

(841) Mendel, R. R. Cell biology of molybdenum. *Biofactors* 2009, 35 (5), 429.

(842) Mendel, R. R.; Kruse, T. Cell biology of molybdenum in plants and humans. *Biochim. Biophys. Acta* 2012, 1823 (9), 1568.

(843) Schwarz, G.; Mendel, R. R.; Ribbe, M. W. Molybdenum cofactors, enzymes and pathways. *Nature* 2009, 460 (7257), 839.

(844) Mukherjee, B.; Patra, B.; Mahapatra, S.; Banerjee, P.; Tiwari, A.; Chatterjee, M. Vanadium—an element of atypical biological significance. *Toxicol. Lett.* 2004, 150 (2), 135.

(845) Winter, J. M.; Moore, B. S. Exploring the chemistry and biology of vanadium-dependent haloperoxidases. *J. Biol. Chem.* 2009, 284 (28), 18577.

(846) Lewicki, S.; Zdanowski, R.; Krzyzowska, M.; Lewicka, A.; Debski, B.; Niemcewicz, M.; Goniewicz, M. The role of Chromium III in the organism and its possible use in diabetes and obesity treatment. *Ann. Agric. Environ. Med.* 2014, 21 (2), 331.

(847) Yamamoto, A.; Wada, O.; Ono, T. Distribution and chromium-binding capacity of a low-molecular-weight, chromium-binding substance in mice. *J. Inorg. Biochem.* 1984, 22 (2), 91.

(848) Yamamoto, A.; Wada, O.; Manabe, S. Evidence that chromium is an essential factor for biological activity of low-molecular-weight, chromium-binding substance. *Biochem. Biophys. Res. Commun.* 1989, 163 (1), 189.

(849) Vincent, J. B. Mechanisms of chromium action: low-molecular-weight chromium-binding substance. *J. Am. Coll. Nutr.* 1999, 18 (1), 6.

(850) Warren, M. J.; Raux, E.; Schubert, H. L.; Escalante-Semerena, J. C. The biosynthesis of adenosylcobalamin (vitamin B12). *Nat. Prod. Rep.* 2002, 19 (4), 390.

(851) Kobayashi, M.; Shimizu, S. Cobalt proteins. *Eur. J. Biochem.* 1999, 261 (1), 1.

(852) Fong, G. H.; Takeda, K. Role and regulation of prolyl hydroxylase domain proteins. *Cell Death Differ.* 2008, 15 (4), 635.

(853) Hille, R.; Nishino, T.; Bittner, F. Molybdenum enzymes in higher organisms. *Coord. Chem. Rev.* 2011, 255 (9–10), 1179.

(854) Martinez-Reyes, I.; Chandel, N. S. Cancer metabolism: looking forward. *Nat. Rev. Cancer* 2021, 21 (10), 669.

(855) Trevino, S.; Diaz, A. Vanadium and insulin: Partners in metabolic regulation. *J. Inorg. Biochem.* 2020, 208, 111094.
(856) Chen, F.; Shi, X. Intracellular signal transduction of cells in response to carcinogenic metals. *Crit. Rev. Oncol. Hematol.* **2002**, *42* (1), 105.

(857) Li, Y.; Lou, J.; Hong, S.; Hou, D.; Lv, Y.; Guo, Z.; Wang, K.; Xu, Y.; Zhai, Y.; Liu, H. The role of heavy metals in the development of colorectal cancer. *BMC Cancer* **2023**, *23*, 616.

(858) Mu, D.; Tang, H.; Teng, G.; Li, X.; Zhang, Y.; Gao, G.; Wang, D.; Bai, L.; Lian, X.; Wen, M.; et al. Differences of genomic alterations and heavy metals in non-small cell lung cancer with different histological subtypes. *J. Cancer Res. Clin. Oncol.* **2023**, *149* (12), 9999.

(859) Ferretti, V. A.; León, A. E. An Overview of Vanadium and Cell Signaling in Potential Cancer Treatments. *Inorganics* **2022**, *10*, 47.

(860) Fang, Z.; Zhao, M.; Zhen, H.; Chen, L.; Shi, P.; Huang, Z. Genotoxicity of tri- and hexavalent chromium compounds in vivo and their modes of action on DNA damage in vitro. *PLoS One* **2014**, *9* (8), e103194.

(861) Singh, J.; Carlisle, D. L.; Pritchard, D. E.; Patierno, S. R. Chromium-induced genotoxicity and apoptosis: relationship to chromium carcinogenesis (review). *Oncol. Rep.* **1998**, *5* (6), 1307.

(862) Granata, S.; Vivarelli, F.; Morosini, C.; Canistro, D.; Paolini, M.; Fairclough, L. C. Toxicological Aspects Associated with Consumption from Electronic Nicotine Delivery System (ENDS): Focus on Heavy Metals Exposure and Cancer Risk. *Int. J. Mol. Sci.* **2024**, *25* (5), 2737.

(863) Ryu, M. H.; Park, J. H.; Park, J. E.; Chung, J.; Lee, C. H.; Park, H. R. Cobalt chloride stimulates phosphoinositide 3-kinase/Akt signaling through the epidermal growth factor receptor in oral squamous cell carcinoma. *Biocell* **2010**, *34* (1), 15.

(864) Zambelli, B.; Uversky, V. N.; Ciurli, S. Nickel impact on human health: An intrinsic disorder perspective. *Biochim. Biophys. Acta* **2016**, *1864* (12), 1714.

(865) Chen, H.; Giri, N. C.; Zhang, R.; Yamane, K.; Zhang, Y.; Maroney, M.; Costa, M. Nickel ions inhibit histone demethylase JMJD1A and DNA repair enzyme ABH2 by replacing the ferrous iron in the catalytic centers. *J. Biol. Chem.* **2010**, *285* (10), 7374.

(866) Pessoa, J. C.; Etcheverry, S.; Gambino, D. Vanadium compounds in medicine. *Coord. Chem. Rev.* **2015**, *301*, 24.

(867) Tsave, O.; Petanidis, S.; Kioseoglou, E.; Yavropoulou, M. P.; Yovos, J. G.; Anestakis, D.; Tsepa, A.; Salifoglou, A. Role of Vanadium in Cellular and Molecular Immunology: Association with Immune-Related Inflammation and Pharmacotoxicology Mechanisms. *Oxid. Med. Cell Longev.* **2016**, *2016*, 4013639.

(868) Chen, F.; Demers, L. M.; Vallyathan, V.; Ding, M.; Lu, Y.; Castranova, V.; Shi, X. Vanadate induction of NF-kappaB involves IkappaB kinase beta and SAPK/ERK kinase 1 in macrophages. *J. Biol. Chem.* **1999**, *274* (29), 20307.

(869) Pierce, L. M.; Alessandrini, F.; Godleski, J. J.; Paulauskis, J. D. Vanadium-induced chemokine mRNA expression and pulmonary inflammation. *Toxicol. Appl. Pharmacol.* **1996**, *138* (1), 1.

(870) Elberg, G.; Li, J.; Shechter, Y. Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxidation state. Possible role of endogenous vanadium in controlling cellular protein tyrosine kinase activity. *J. Biol. Chem.* **1994**, *269* (13), 9521.

(871) Trevino, S.; Diaz, A.; Sanchez-Lara, E.; Sanchez-Gaytan, B. L.; Perez-Aguilar, J. M.; Gonzalez-Vergara, E. Vanadium in Biological Action: Chemical Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus. *Biol. Trace Elem. Res.* **2019**, *188* (1), 68.

(872) O'Shea, J. J.; McVicar, D. W.; Bailey, T. L.; Burns, C.; Smyth, M. J. Activation of human peripheral blood T lymphocytes by pharmacological induction of protein-tyrosine phosphorylation. *Proc. Natl. Acad. Sci. U.S.A.* **1992**, *89* (21), 10306.

(873) Shrivastava, R.; Upreti, R. K.; Seth, P. K.; Chaturvedi, U. C. Effects of chromium on the immune system. *FEMS Immunol. Med. Microbiol. 2002*, *34* (1), 1.

(874) Glaser, U.; Hochrainer, D.; Kloppel, H.; Kuhnen, H. Low level chromium (VI) inhalation effects on alveolar macrophages and immune functions in Wistar rats. *Arch. Toxicol.* **1985**, *57* (4), 250.

(875) Lawrence, H.; Deehan, D. J.; Holland, J. P.; Anjum, S. A.; Mawdesley, A. E.; Kirby, J. A.; Tyson-Capper, A. J. Cobalt ions recruit inflammatory cells in vitro through human Toll-like receptor 4. *Biochem. Biophys. Rep.* **2016**, *7*, 374.

(876) Devitt, B. M.; Queally, J. M.; Vioreanu, M.; Butler, J. S.; Murray, D.; Doran, P. P.; O'Byrne, J. M. Cobalt ions induce chemokine secretion in a variety of systemic cell lines. *Acta Orthop.* **2010**, *81* (6), 756.

(877) Diez-Tercero, L.; Delgado, L. M.; Bosch-Rue, E.; Perez, R. A. Evaluation of the immunomodulatory effects of cobalt, copper and magnesium ions in a pro inflammatory environment. *Sci. Rep.* **2021**, *11*, 11707.

(878) Cavani, A. Breaking tolerance to nickel. *Toxicology* **2005**, *209* (2), 119.

(879) Cavani, A.; Nasorri, F.; Ottaviani, C.; Sebastiani, S.; De Pita, O.; Girolomoni, G. Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. *J. Immunol.* **2003**, *171* (11), 5760.

(880) Rundle, C.; Jacob, S. E. Chelation Therapy for Nickel Allergy. *J. Dermatol. Nur. Assoc.* **2017**, *9*, 46.

(881) Baran, E. J. Vanadium detoxification: chemical and biochemical aspects. *Chem. Biodivers.* **2008**, *5* (8), 1475.

(882) Jones, M. M.; Basinger, M. A. Chelate antidotes for sodium vanadate and vanadyl sulfate intoxication in mice. *J. Toxicol. Environ. Health* **1983**, *12* (4-6), 749.

(883) Domingo, J. L.; Llobet, J. M.; Corbella, J. Protection of mice against the lethal effects of sodium metavanadate: a quantitative comparison of a number of chelating agents. *Toxicol. Lett.* **1985**, *26* (2-3), 95.

(884) Domingo, J. L.; Llobet, J. M.; Tomas, J. M.; Corbella, J. Influence of chelating agents on the toxicity, distribution and excretion of vanadium in mice. *J. Appl. Toxicol.* **1986**, *6* (5), 337.

(885) Wilkins, P. C.; Johnson, M. D.; Holder, A. A.; Crans, D. C. Reduction of vanadium(V) by L-ascorbic acid at low and neutral pH: kinetic, mechanistic, and spectroscopic characterization. *Inorg. Chem.* **2006**, *45* (4), 1471.

(886) Domingo, J. L. Vanadium: a review of the reproductive and developmental toxicity. *Reprod. Toxicol.* **1996**, *10* (3), 175.

(887) Scior, T.; Guevara-Garcia, A.; Bernard, P.; Do, Q. T.; Domeyer, D.; Laufer, S. Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review. *Mini Rev. Med. Chem.* **2005**, *5* (11), 995.

(888) Srivastava, A. K.; Mehdi, M. Z. Insulino-mimetic and anti-diabetic effects of vanadium compounds. *Diabet. Med.* **2005**, *22* (1), 2.

(889) Goldwaser, I.; Gefel, D.; Gershonov, E.; Fridkin, M.; Shechter, Y. Insulin-like effects of vanadium: basic and clinical implications. *J. Inorg. Biochem.* **2000**, *80* (1-2), 21.

(890) Thompson, K. H. Vanadium and diabetes. *Biofactors* **1999**, *10* (1), 43.

(891) McNeill, J. H.; Yuen, V. G.; Hoveyda, H. R.; Orvig, C. Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. *J. Med. Chem.* **1992**, *35* (8), 1489.

(892) Orvig, C.; Caravan, P.; Gelmini, L.; Glover, N.; Herring, F. G.; Li, H.; McNeill, J. H.; Rettig, S. J.; Setyawati, I. A.; et al. Reaction chemistry of BMOV, bis(maltolato)oxovanadium(IV), a potent insulin mimetic agent. *J. Am. Chem. Soc.* **1995**, *117*, 12759.

(893) Fujimoto, S.; Fujii, K.; Yasui, H.; Matsushita, R.; Takada, J.; Sakurai, H. Long-Term Acting and Orally Active Vanadyl-Methyl-picolinate Complex with Hypoglycemic Activity in Streptozotocin-Induced Diabetic Rats. *J. Clin. Biochem. Nutr.* **1997**, *23*, 113.

(894) Barrio, D. A.; Etcheverry, S. B. Potential use of vanadium compounds in therapeutics. *Curr. Med. Chem.* **2010**, *17* (31), 3632.

(895) Vincent, J. B. The biochemistry of chromium. *J. Nutr.* **2000**, *130* (4), 715.

(896) Morris, B. W.; MacNeil, S.; Hardisty, C. A.; Heller, S.; Burgin, C.; Gray, T. A. Chromium homeostasis in patients with type II (NIDDM) diabetes. *J. Trace Elem. Med. Biol.* **1999**, *13* (1-2), 57.

(897) Anderson, R. A. Chromium and diabetes. *Nutrition* **1999**, *15* (9), 720.

(898) Maret, W. Chromium Supplementation in Human Health, Metabolic Syndrome, and Diabetes. *Met. Ions Life Sci.* **2019**, *19*, 15.
(899) Zhao, F.; Pan, D.; Wang, N.; Xia, H.; Zhang, H.; Wang, S.; Sun, G. Effect of Chromium Supplementation on Blood Glucose and Lipid Levels in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis. *Biol. Trace Elem. Res.* **2022**, *200* (2), 516.

(900) Schaffner, A.; Li, X.; Gomez-Llorente, Y.; Leandrou, E.; Memou, A.; Clemente, N.; Yao, C.; Afsari, F.; Zhi, L.; Pan, N.; et al. Vitamin B(12) modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. *Cell Res.* **2019**, *29* (4), 313.

(901) Catalani, S.; Rizzetti, M. C.; Padovani, A.; Apostoli, P. Neurotoxicity of cobalt. *Hum. Exp. Toxicol.* **2012**, *31* (5), 421.

(902) Lan, A. P.; Chen, J.; Chai, Z. F.; Hu, Y. The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated mechanisms. *Biometals* **2016**, *29* (4), 665.

(903) Genchi, G.; Carocci, A.; Lauria, G.; Sinicropi, M. S.; Catalano, A. Nickel: Human Health and Environmental Toxicology. *Int. J. Environ. Res. Public Health* **2020**, *17* (3), 679.

(904) Mechler, K.; Mountford, W. K.; Hoffmann, G. F.; Ries, M. Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency. *Genet. Med.* **2015**, *17* (12), 965.

(905) Lee, H. J.; Adham, I. M.; Schwarz, G.; Kneussel, M.; Sass, J. O.; Engel, W.; Reiss, J. Molybdenum cofactor-deficient mice resemble the phenotype of human patients. *Hum. Mol. Genet.* **2002**, *11* (26), 3309.

(906) Veldman, A.; Santamaria-Araujo, J. A.; Sollazzo, S.; Pitt, J.; Gianello, R.; Yaplito-Lee, J.; Wong, F.; Ramsden, C. A.; Reiss, J.; Cook, L.; et al. Successful treatment of molybdenum cofactor deficiency type A with cPMP. *Pediatrics* **2010**, *125* (5), e1249.

(907) Horak, E.; Sunderman, F. W., Jr; Sarkar, B. Comparisons of antidotal efficacy of chelating drugs upon acute toxicity of Ni(II) in rats. *Res. Commun. Chem. Pathol. Pharmacol.* **1976**, *14* (1), 153.

(908) Sunderman, F. W.; Sunderman, F. W., Jr. Nickel poisoning. VIII. Dithiocarb: a new therapeutic agent for persons exposed to nickel carbonyl. *Am. J. Med. Sci.* **1958**, *236* (1), 26.

(909) Benoit, S. L.; Schmalstig, A. A.; Glushka, J.; Maier, S. E.; Edison, A. S.; Maier, R. J. Nickel chelation therapy as an approach to combat multi-drug resistant enteric pathogens. *Sci. Rep.* **2019**, *9*, 13851.

(910) Benoit, S. L.; Maier, R. J. The nickel-chelator dimethylglyoxime inhibits human amyloid beta peptide in vitro aggregation. *Sci. Rep.* **2021**, *11*, 6622.

(911) Salehi, S.; Moghaddama, S. M. M.; Tarina, M.; Saljoogha, A. S. Pharmaceutical Nickel(II) Chelation Properties of 3-Hydroxyflaven, Deferiprone and Maltol Metal Chelators: A Density Functional Study. *Phys. Chem. Res.* **2020**, *8*, 91.

(912) Kasprzak, K. S.; Diwan, B. A.; Rice, J. M. Iron accelerates while magnesium inhibits nickel-induced carcinogenesis in the rat kidney. *Toxicology* **1994**, *90* (1–2), 129.

(913) Jiang, M.; Wu, R.; Liu, D.; Wang, X. Utilizing Ni(II) complex for metal drug-gel particles in cervical cancer treatment and designing novel drugs through machine learning methods. *Sci. Rep.* **2024**, *14*, 5421.

(914) Andersen, O. Principles and recent developments in chelation treatment of metal intoxication. *Chem. Rev.* **1999**, *99* (9), 2683.

(915) Andersen, O. Chemical and biological considerations in the treatment of metal intoxications by chelating agents. *Mini Rev. Med. Chem.* **2004**, *4*, 11.

(916) Aposhian, H. V.; Maiorino, R. M.; Gonzalez-Ramirez, D.; Zuniga-Charles, M.; Xu, Z.; Hurlbut, K. M.; Junco-Munoz, P.; Dart, R. C.; Aposhian, M. M. Mobilization of heavy metals by newer, therapeutically useful chelating agents. *Toxicology* **1995**, *97* (1–3), 23.

(917) Domingo, J. L.; Gomez, M.; Llobet, J. M.; Corbella, J. Chelating agents in the treatment of acute vanadyl sulphate intoxication in mice. *Toxicology* **1990**, *62* (2), 203.

(918) Li, J.; Elberg, G.; Crans, D. C.; Shechter, Y. Evidence for the distinct vanadyl(+4)-dependent activating system for manifesting insulin-like effects. *Biochemistry* **1996**, *35* (25), 8314.

(919) Goldwaser, I.; Li, J.; Gershonov, E.; Armoni, M.; Karnieli, E.; Fridkin, M.; Shechter, Y. L-Glutamic acid gamma-monohydroxamate. A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo. *J. Biol. Chem.* **1999**, *274* (37), 26617.

(920) Krejsa, C. M.; Nadler, S. G.; Esselstyn, J. M.; Kavanagh, T. J.; Ledbetter, J. A.; Schieven, G. L. Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors. Redox independent activation of NF-kappaB. *J. Biol. Chem.* **1997**, *272* (17), 11541.

(921) Amaral, L.; Moniz, T.; Silva, A. M. N.; Rangel, M. Vanadium Compounds with Antidiabetic Potential. *Int. J. Mol. Sci.* **2023**, *24*, 15675.

(922) Boden, G.; Chen, X.; Ruiz, J.; van Rossum, G. D.; Turco, S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. *Metabolism* **1996**, *45* (9), 1130.

(923) Irving, E.; Stoker, A. W. Vanadium Compounds as PTP Inhibitors. *Molecules* **2017**, *22*, 2269.

(924) Blanusa, M.; Varnai, V. M.; Piasek, M.; Kostial, K. Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. *Curr. Med. Chem.* **2005**, *12* (23), 2771.

(925) Banner, W., Jr.; Koch, M.; Capin, D. M.; Hopf, S. B.; Chang, S.; Tong, T. G. Experimental chelation therapy in chromium, lead, and boron intoxication with N-acetylcysteine and other compounds. *Toxicol. Appl. Pharmacol.* **1986**, *83* (1), 142.

(926) Behari, J. R.; Tandon, S. K. Chelation in metal intoxication. VIII. Removal of chromium from organs of potassium chromate administered rats. *Clin. Toxicol.* **1980**, *16* (1), 33.

(927) Walpole, I. R.; Johnston, K.; Clarkson, R.; Wilson, G.; Bower, G. Acute chromium poisoning in a 2 year old child. *Aust. Paediatr. J.* **1985**, *21* (1), 65.

(928) Korallus, U.; Harzdorf, C.; Lewalter, J. Experimental bases for ascorbic acid therapy of poisoning by hexavalent chromium compounds. *Int. Arch. Occup. Environ. Health* **1984**, *53* (3), 247.

(929) Tandon, S. K.; Srivastava, L. Chelation in metal intoxication XVII: Antidotal efficacy of polyaminocarboxylic acids on acute chromate toxicity. *Arch. Toxicol.* **1985**, *57* (3), 212.

(930) Molina-Jijon, E.; Zarco-Marquez, G.; Medina-Campos, O. N.; Zatarain-Barron, Z. L.; Hernandez-Pando, R.; Pinzon, E.; Zavaleta, R. M.; Tapia, E.; Pedraza-Chaverri, J. Deferoxamine pretreatment prevents Cr(VI)-induced nephrotoxicity and oxidant stress: role of Cr(VI) chelation. *Toxicology* **2012**, *291* (1–3), 93.

(931) McLoughlin, T. J.; Tsivitse, S. K.; Edwards, J. A.; Aiken, B. A.; Pizza, F. X. Deferoxamine reduces and nitric oxide synthase inhibition increases neutrophil-mediated myotube injury. *Cell Tissue Res.* **2003**, *313* (3), 313.

(932) Duran, M.; Beemer, F. A.; van de Heiden, C.; Korteland, J.; de Bree, P. K.; Brink, M.; Wadman, S. K.; Lombeck, I. Combined deficiency of xanthine oxidase and sulphite oxidase: a defect of molybdenum metabolism or transport? *J. Inherit. Metab. Dis.* **1978**, *1*, 175.

(933) Vasto, S.; Baldassano, D.; Sabatino, L.; Caldarella, R.; Di Rosa, L.; Baldassano, S. The Role of Consumption of Molybdenum Biofortified Crops in Bone Homeostasis and Healthy Aging. *Nutrients* **2023**, *15*, 1022.

(934) Schreiber, S. L. The Rise of Molecular Glues. *Cell* **2021**, *184* (1), 3.

(935) Rodriguez, R.; Miller, K. M. Unravelling the genomic targets of small molecules using high-throughput sequencing. *Nat. Rev. Genet.* **2014**, *15* (12), 783.

(936) Kruidenier, L.; Chung, C. W.; Cheng, Z.; Liddle, J.; Che, K.; Joberty, G.; Bantscheff, M.; Bountra, C.; Bridges, A.; Diallo, H.; et al. Kruidenier et al. reply. *Nature* **2014**, *514* (7520), E2.

(937) Parrot, M.; Tajmouati, H.; da Silva, V. B. R.; Atwood, B. R.; Fourcade, R.; Gaston-Mathe, Y.; Do Huu, N.; Perron, Q. Integrating synthetic accessibility with AI-based generative drug design. *J. Cheminform* **2023**, *15*, 83.

(938) Perron, Q.; Mirguet, O.; Tajmouati, H.; Skiredj, A.; Rojas, A.; Gohier, A.; Ducrot, P.; Bourguignon, M. P.; Sansilvestri-Morel, P.; Do Huu, N.; et al. Deep generative models for ligand-based de novo design applied to multi-parametric optimization. *J. Comput. Chem.* **2022**, *43* (10), 692.